Dolor Technologies

What Dolor Technologies does

Dolor Technologies is a privately held U.S. medical device company founded in 2010 and headquartered in South Jordan, Utah, with a headcount in the 11-50 range. Under CEO Steven Eror, the company develops and markets the Sphenocath, a specialized drug delivery system engineered to administer medication directly to the sphenopalatine ganglion (SPG) — a parasympathetic ganglion implicated in headache, facial pain, and certain autonomic conditions. The Sphenocath platform is positioned as a procedural tool for clinicians seeking a minimally invasive route to deposit therapeutic agents at the SPG, differentiating it from systemic pharmacologic approaches to headache management.

The company's commercial footprint is narrow: its only disclosed capital event is an $800,000 financing in January 2014 from undisclosed investors, and there is no public record of subsequent funding rounds, partnerships, distribution agreements, or product line extensions. The corporate website (sphenocath.com) functions as a product information resource rather than a broad commercial portal, consistent with a focused, single-product device strategy.

The business model is built around direct sales and distribution of a single proprietary procedural device to headache specialists, pain management physicians, otolaryngologists, and related clinical practices. There is no evidence of software, services, consumables subscriptions, or tiered pricing in the available data, and customer composition, geographic reach, and revenue figures are not disclosed. The company's operating posture since 2010 suggests ongoing but limited commercialization, with continuity of leadership and product offering rather than visible scaling.

Name

Dolor Technologies

Website

https://sphenocath.com

Company type

Private

Founded year

2010

Headcount range

11–50 employees

Short description

Dolor Technologies is a privately held U.S. medical device company that develops and markets the Sphenocath, a transnasal drug delivery system designed to administer medication to the sphenopalatine ganglion for clinicians treating headache and facial pain conditions.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

• Medical device manufacturing
• Drug delivery systems
• Sphenopalatine ganglion catheter
• Interventional pain management
• Headache treatment devices

Headquarters

HQ city

South Jordan

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Core offering

Dolor Technologies manufactures and sells the Sphenocath, a specialized catheter-based drug delivery system designed to deliver medication directly to the sphenopalatine ganglion (SPG). The device is intended for use by clinicians in the treatment of head and facial pain conditions, providing a targeted drug delivery approach via an intranasal route to the SPG.

Differentiator

Problem solved

Functional benefit

Products and services

• Sphenocath A catheter-based drug delivery system designed to administer medication to the sphenopalatine ganglion (SPG) for the treatment of head, facial, and migraine pain. Intended for use by clinicians in pain management and headache treatment settings.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Emerging players

• Theranica Bio-Electronics: Maker of Nerivio, a wearable neuromodulation device FDA-cleared for acute and preventive migraine. Comparable as a non-pharmacologic device competing for the same migraine patient and prescriber audience.
• Curan Medical: Developer of the Curapod, a neuromodulation device for acute and preventive treatment of migraine. Comparable as a smaller, focused headache-therapy device competitor targeting the same physician specialty channels.

Broad incumbents

• AptarGroup (Pharma Division): Global supplier of nasal and pulmonary drug delivery devices, dispensing systems, and active material solutions used by pharmaceutical companies. Comparable as a provider of nasal delivery technology to the broader pharma market.
• Teleflex: Large medical device manufacturer with a portfolio including nasal drug delivery and airway management products. Comparable as an established medtech player in nasal delivery hardware.

Others

• AbbVie (Allergan): Markets BOTOX for chronic migraine and other leading headache therapies. Comparable as a major competitor for migraine patient share and a potential acquirer of specialty headache device assets.
• Biohaven Pharmaceuticals (now Pfizer): Developer of Nurtec ODT, a leading oral CGRP antagonist for migraine. Comparable as a major therapeutic competitor shaping treatment patterns for headache patients who might otherwise receive procedural interventions.

Direct peers

• OptiNose: Specialty pharmaceutical company developing and commercializing nasal drug delivery products, including migraine therapy (Onzetra Xsail). Directly comparable to Dolor Technologies as both companies use intranasal delivery to address migraine and headache indications.
• Impel NeuroPharma: Developed the POD technology for intranasal delivery of drugs to the upper nasal cavity, including acute migraine treatment (Trudhesa). Closely comparable to the Sphenocath as a nasal-delivery device targeting the sphenopalatine region for headache therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/sphenocath
• Facebookfacebook.com/228193680722786
• LinkedInlinkedin.com/company/3693574

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dolor Technologies